BioLife Solutions Inc (BLFS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BioLife Solutions Inc stock (BLFS) is currently trading at $19.86. BioLife Solutions Inc PS ratio (Price-to-Sales) is 9.89. Analyst consensus price target for BLFS is $32.40. WallStSmart rates BLFS as Sell.
- BLFS PE ratio analysis and historical PE chart
- BLFS PS ratio (Price-to-Sales) history and trend
- BLFS intrinsic value — DCF, Graham Number, EPV models
- BLFS stock price prediction 2025 2026 2027 2028 2029 2030
- BLFS fair value vs current price
- BLFS insider transactions and insider buying
- Is BLFS undervalued or overvalued?
- BioLife Solutions Inc financial analysis — revenue, earnings, cash flow
- BLFS Piotroski F-Score and Altman Z-Score
- BLFS analyst price target and Smart Rating
BioLife Solutions Inc
📊 No data available
Try selecting a different time range
Smart Analysis
BioLife Solutions Inc (BLFS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
BioLife Solutions Inc (BLFS) Key Strengths (2)
Revenue surging 63.90% year-over-year
106.30% of shares held by major funds and institutions
Supporting Valuation Data
BioLife Solutions Inc (BLFS) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Earnings declining -13.90%, profits shrinking
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very expensive at 9.9x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
BioLife Solutions Inc (BLFS) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 63.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including PEG Ratio (65.38), Price/Sales (9.89), Price/Book (2.56) suggest expensive pricing. Growth concerns include EPS Growth at -13.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -3.37%, Operating Margin at -0.32%, Profit Margin at -4.78%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -3.37% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 63.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BLFS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BLFS's Price-to-Sales ratio of 9.89x trades 16% below its historical average of 11.71x (60th percentile). The current valuation is 91% below its historical high of 104.67x set in Aug 2018, and 753% above its historical low of 1.16x in Dec 2011. Over the past 12 months, the PS ratio has compressed from ~12.1x as trailing revenue scaled faster than the stock price.
Compare BLFS with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for BioLife Solutions Inc (BLFS) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
BioLife Solutions Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 96M with 64% growth year-over-year. The company is currently unprofitable, posting a -478.0% profit margin.
Key Findings
Revenue growing at 64% YoY, reaching 96M. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
Generating 3M in free cash flow and 5M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -478.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can BioLife Solutions Inc maintain 64%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.94, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact BioLife Solutions Inc.
Bottom Line
BioLife Solutions Inc is a high-conviction growth story with revenue accelerating at 64% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -478.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About BioLife Solutions Inc(BLFS)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.